Paid Plans
Want to analyze multiple companies at once? Paid plans let you compare up to 5 stocks side by side.
Sign Up
E
456070
vs
K
KOSPI 200
Over the past 12 months, ENCell Co Ltd has underperformed KOSPI 200, delivering a return of -65% compared to KOSPI 200's +50% growth.
Stocks Performance
456070 vs KOSPI 200
Performance Gap
456070 vs KOSPI 200
Performance By Year
456070 vs KOSPI 200
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
ENCell Co Ltd
Glance View
ENCell Co Ltd is a South Korean biotechnology company focused on cell therapy, especially treatments built from mesenchymal stem cells. It develops these therapies from lab research through clinical testing and then works to turn them into approved medicines for serious diseases where patients have limited treatment options. The company makes money mainly by developing its own drug candidates and, if they are approved, selling those therapies to hospitals and healthcare providers. It may also earn income through research collaborations, licensing, or other development-related agreements tied to its cell therapy technology. Its customers are not ordinary consumers but doctors, hospitals, and partners in the pharmaceutical and biotech chain. What sets ENCell apart is its role as a specialist in regenerative medicine rather than a broad drugmaker. Cell therapy businesses are built around living cells, which makes the science, manufacturing, and quality control very different from traditional pills or injections. That gives ENCell a place in the part of healthcare industry that tries to repair or replace damaged tissue using engineered cells.